In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin
Аbstrасt Objectives This study aimed to investigate in-hospital mortality rates in patients with coronavirus disease (COVID-19) according to enoxaparin and heparin use. Methods This retrospective cohort study included 962 patients admitted to two hospitals in Kuwait with a confirmed diagnosis of COV...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-10-01
|
| Series: | Clinical and Applied Thrombosis/Hemostasis |
| Online Access: | https://doi.org/10.1177/10760296221131802 |
| _version_ | 1797985620549697536 |
|---|---|
| author | Moudhi Alroomi MD Ahmad Alsaber MD Bader Al-Bader MD Farah Almutairi MD Haya Malhas MD Jiazhu Pan MD Kobalava D. Zhanna MD Maryam Ramadhan MD Mohammad Al Saleh MD Mohammed Abdullah MD Naser Alotaibi MD Noor AlNasrallah MD Rajesh Rajan MD Soumoud Hussein MD Wael Aboelhassan MD |
| author_facet | Moudhi Alroomi MD Ahmad Alsaber MD Bader Al-Bader MD Farah Almutairi MD Haya Malhas MD Jiazhu Pan MD Kobalava D. Zhanna MD Maryam Ramadhan MD Mohammad Al Saleh MD Mohammed Abdullah MD Naser Alotaibi MD Noor AlNasrallah MD Rajesh Rajan MD Soumoud Hussein MD Wael Aboelhassan MD |
| author_sort | Moudhi Alroomi MD |
| collection | DOAJ |
| description | Аbstrасt Objectives This study aimed to investigate in-hospital mortality rates in patients with coronavirus disease (COVID-19) according to enoxaparin and heparin use. Methods This retrospective cohort study included 962 patients admitted to two hospitals in Kuwait with a confirmed diagnosis of COVID-19. Cumulative all-cause mortality rate was the primary outcome. Results A total of 302 patients (males, 196 [64.9%]; mean age, 57.2 ± 14.6 years; mean body mass index, 29.8 ± 6.5 kg/m 2 ) received anticoagulation therapy. Patients receiving anticoagulation treatment tended to have pneumonia (n = 275 [91.1%]) or acute respiratory distress syndrome (n = 106 [35.1%]), and high D-dimer levels (median [interquartile range]: 608 [523;707] ng/mL). The mortality rate in this group was high (n = 63 [20.9%]). Multivariable logistic regression, the Cox proportional hazards, and Kaplan-Meier models revealed that the use of therapeutic anticoagulation agents affected the risk of all-cause cumulative mortality. Conclusion Age, hypertension, pneumonia, therapeutic anticoagulation, and methylprednisolone use were found to be strong predictors of in-hospital mortality. In elderly hypertensive COVID-19 patients on therapeutic anticoagulation were found to have 2.3 times higher risk of in-hospital mortality. All cause in-hospital mortality rate in the therapeutic anticoagulation group was up to 21%. |
| first_indexed | 2024-04-11T07:20:49Z |
| format | Article |
| id | doaj.art-55eea57c66a84b45a606bf499d0b9d58 |
| institution | Directory Open Access Journal |
| issn | 1938-2723 |
| language | English |
| last_indexed | 2024-04-11T07:20:49Z |
| publishDate | 2022-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical and Applied Thrombosis/Hemostasis |
| spelling | doaj.art-55eea57c66a84b45a606bf499d0b9d582022-12-22T04:37:14ZengSAGE PublishingClinical and Applied Thrombosis/Hemostasis1938-27232022-10-012810.1177/10760296221131802In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and HeparinMoudhi Alroomi MD0Ahmad Alsaber MD1Bader Al-Bader MD2Farah Almutairi MD3Haya Malhas MD4Jiazhu Pan MD5Kobalava D. Zhanna MD6Maryam Ramadhan MD7Mohammad Al Saleh MD8Mohammed Abdullah MD9Naser Alotaibi MD10Noor AlNasrallah MD11Rajesh Rajan MD12Soumoud Hussein MD13Wael Aboelhassan MD14 Department of Infectious Diseases, Infectious Diseases Hospital, Shuwaikh Medical Area, Kuwait Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK Department of Medicine, Farwaniya Hospital, Farwaniya, Kuwait Department of Medicine, Farwaniya Hospital, Farwaniya, Kuwait Department of Medicine, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK Department of Internal Medicine with the Subspecialty of Cardiology and Functional Diagnostics Named after V.S. Moiseev, Institute of Medicine, Peoples’ Friendship University of Russia (RUDN University), Moscow, Russian Federation Department of Obstetrics and Gynaecology, Maternity Hospital, Shuwaikh Medical Area, Kuwait Department of Medicine, Farwaniya Hospital, Farwaniya, Kuwait Department of Infectious Diseases, Infectious Diseases Hospital, Shuwaikh Medical Area, Kuwait Department of Medicine, Al Adan Hospital, Hadiya, Kuwait Department of Medicine, Al Adan Hospital, Hadiya, Kuwait Department of Cardiology, Sabah Al Ahmed Cardiac Centre, Al Amiri Hospital, Kuwait City, Kuwait Department of Medicine, Al Amiri Hospital, Kuwait City, Kuwait Division of Gastroenterology, Department of Medicine, Jaber Al Ahmed Hospital, South Surra, KuwaitАbstrасt Objectives This study aimed to investigate in-hospital mortality rates in patients with coronavirus disease (COVID-19) according to enoxaparin and heparin use. Methods This retrospective cohort study included 962 patients admitted to two hospitals in Kuwait with a confirmed diagnosis of COVID-19. Cumulative all-cause mortality rate was the primary outcome. Results A total of 302 patients (males, 196 [64.9%]; mean age, 57.2 ± 14.6 years; mean body mass index, 29.8 ± 6.5 kg/m 2 ) received anticoagulation therapy. Patients receiving anticoagulation treatment tended to have pneumonia (n = 275 [91.1%]) or acute respiratory distress syndrome (n = 106 [35.1%]), and high D-dimer levels (median [interquartile range]: 608 [523;707] ng/mL). The mortality rate in this group was high (n = 63 [20.9%]). Multivariable logistic regression, the Cox proportional hazards, and Kaplan-Meier models revealed that the use of therapeutic anticoagulation agents affected the risk of all-cause cumulative mortality. Conclusion Age, hypertension, pneumonia, therapeutic anticoagulation, and methylprednisolone use were found to be strong predictors of in-hospital mortality. In elderly hypertensive COVID-19 patients on therapeutic anticoagulation were found to have 2.3 times higher risk of in-hospital mortality. All cause in-hospital mortality rate in the therapeutic anticoagulation group was up to 21%.https://doi.org/10.1177/10760296221131802 |
| spellingShingle | Moudhi Alroomi MD Ahmad Alsaber MD Bader Al-Bader MD Farah Almutairi MD Haya Malhas MD Jiazhu Pan MD Kobalava D. Zhanna MD Maryam Ramadhan MD Mohammad Al Saleh MD Mohammed Abdullah MD Naser Alotaibi MD Noor AlNasrallah MD Rajesh Rajan MD Soumoud Hussein MD Wael Aboelhassan MD In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin Clinical and Applied Thrombosis/Hemostasis |
| title | In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin |
| title_full | In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin |
| title_fullStr | In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin |
| title_full_unstemmed | In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin |
| title_short | In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin |
| title_sort | in hospital mortality rates in sars cov 2 patients treated with enoxaparin and heparin |
| url | https://doi.org/10.1177/10760296221131802 |
| work_keys_str_mv | AT moudhialroomimd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin AT ahmadalsabermd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin AT baderalbadermd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin AT farahalmutairimd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin AT hayamalhasmd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin AT jiazhupanmd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin AT kobalavadzhannamd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin AT maryamramadhanmd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin AT mohammadalsalehmd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin AT mohammedabdullahmd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin AT naseralotaibimd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin AT nooralnasrallahmd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin AT rajeshrajanmd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin AT soumoudhusseinmd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin AT waelaboelhassanmd inhospitalmortalityratesinsarscov2patientstreatedwithenoxaparinandheparin |